About US
Contact us
-
Jardiance sparks Boehringer Ingelheim's 2021 growth, with more likely on the wayAmid its global push to reach more patients with SGLT2 inhibitor Jardiance, Boehringer Ingelheimreportedsolid sales growth for the med last year. Now, armed with two new FDA approvals in a span of si2022/4/6
-
As AstraZeneca sounds the slowdown alarm in China, Jefferies beats the drum for growing branded drug marketChina’s aggressive efforts to lower drug costs are unnerving some investors. Just consider AstraZeneca: The largest multinational pharma in China is projecting a mid-single-digit percentage decline i2022/4/2
-
Aurobindo to turn out lights at troubled New Jersey plant, putting 99 jobs on the chopping blockAn Aurobindo plant that received a scathing FDA rebuke several years back is shutting its doors for good. Indian generics giant Aurobindo is closing shop at its Aurolife Pharma unit in Dayton,2022/4/2
-
Roche's Chugai pays Halozyme $25M to access subcutaneous delivery techChugai Pharmaceutical has struck a deal for a subcutaneous drug delivery technology,payingHalozyme Therapeutics $25 million upfront to use its Enhanze enzyme against an undisclosed target. The2022/3/30
-
In a busy month, Pfizer extends recall of blood pressure meds to the UKAdd another country to the recall list for Pfizer’s blood pressure medicines. Monday, the companypulled(PDF) one lot of Accuretic off shelves in the U.K., continuing its busy month of voluntary2022/3/30
-
Aurobindo strikes branded generics buyout to build biosimilars 'launch pad' in IndiaAurobindo Pharma is already a generics force to be reckoned with in the U.S. Now, the company has clinched a deal to tap into the burgeoning biosimilars market in its home country of India. Aur2022/3/28
-
On a roll, Sanofi raises Dupixent's peak sales target to €13B-plusOver the years, asSanofi and Regeneron's Dupixentracked up new indications and approached the French pharma giant's 10 billion euro peak sales goal, analysts had started to wonder whether the drug mi2022/3/28
-
Genentech suffers loss in Esbriet patent dispute with Sandoz, Teva and moreAfter whittling down Genentech’s defenses at a bench trial last fall, Novartis’ Sandoz unit has removed a major hurdle on the path to launching itsEsbriet copycat. A Delaware federal judge has2022/3/25
-
Merck telegraphs closure of Pennsylvania antibiotics plant that employs 300Some 300 Merck & Co. staffers’ jobs are on the cutting board after the company confirmed plans to shutter its Cherokee manufacturing plant. Merck aims to mothball production at the facility2022/3/25
-
Merck, building on Keytruda’s landmark biomarker nod, pressures GSK's limited I-O position with new FDA approvalIn a historic FDA go-ahead in 2017, Merck & Co.’s Keytruda became the first treatment for cancers with a specific genetic feature regardless of their location. Now, the immunotherapy has expanded2022/3/23